{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.3","value":"0.19"},{"groupId":"OG001","spread":"42.5","value":"0.96"},{"groupId":"OG002","spread":"500","value":"9.19"},{"comment":"Only 1 participant analyzed","groupId":"OG003","spread":"NA","value":"140"},{"groupId":"OG004","spread":"85.1","value":"81.3"},{"groupId":"OG005","spread":"32.6","value":"197"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"3"}],"units":"Participants"}],"title":"C1D1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"39.9","value":"0.25"},{"comment":"Only 1 participant analyzed","groupId":"OG001","spread":"NA","value":"2.99"},{"groupId":"OG002","spread":"372","value":"19.7"},{"comment":"Only 1 participant analyzed","groupId":"OG003","spread":"NA","value":"163"},{"groupId":"OG004","spread":"90.0","value":"207"},{"groupId":"OG005","spread":"40.2","value":"450"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"3"}],"units":"Participants"}],"title":"C2D8"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"3"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants in Arm A received 60 mg dose of RO7297089 as a flat dose at each scheduled study drug administration visit","id":"OG000","title":"Dose Escalation Cohort 1: RO7297089"},{"description":"Participants in Arm A received 180 mg dose of RO7297089 as a flat dose at each scheduled study drug administration visit","id":"OG001","title":"Dose Escalation Cohort 2: RO7297089"},{"description":"Participants in Arm A received 360 mg dose of RO7297089 as a flat dose at each scheduled study drug administration visit","id":"OG002","title":"Dose Escalation Cohort 3: RO7297089"},{"description":"Participants in Arm A received 1080 mg dose of RO7297089 as a flat dose at each scheduled study drug administration visit","id":"OG003","title":"Dose Escalation Cohort 4: RO7297089"},{"description":"Participants in Arm B received the 1080 mg dose of RO7297089 as a split dose divided over two days (Days 1 and 2). The full target dose wasadministered at subsequent study drug administration visits.","id":"OG004","title":"Dose Escalation Backfill Cohort 4: RO7297089"},{"description":"Participants in Arm B received the 1850 mg dose of RO7297089 as a split dose divided over two days (Days 1 and 2). The full target dose was administered at subsequent study drug administration visits.","id":"OG005","title":"Dose Escalation Cohort 5: RO7297089"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Only those participants who received full dose were included in the results summary","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1, Cycle 2 Day 8","title":"Minimum Concentration Observed (Cmin) of RO7297089","type":"SECONDARY","unitOfMeasure":"ug/mL"}